Tag: Malaria

19 Oct 2016

Zydus Cadila to collaborate with MMV on new anti-malaria drug

MMV (Medicines for Malaria Venture) and Zydus Cadila (Indian pharmaceutical company headquartered at Ahmedabad in Gujarat state of western India) have announced a collaboration to develop the investigational antimalarial compound MMV253.

“Zydus Cadila and Medicines for Malaria Venture (MMV) announced a collaboration to develop the investigational anti-malarial compound, MMV674253. Zydus will lead the development of the novel compound and MMV will provide support, including scientific expertise and access to tools in malaria drug development and delivery,” Zydus Cadila’s listed group firm Cadila Healthcare said in a BSE filing.

“Malaria is a major global health risk and its menace has only worsened with the problem of artemisinin-resistance. By collaborating with Medicines for Malaria Venture in this initiative, we hope to usher in a step change in the treatment of this deadly disease,” said Pankaj R. Patel, Chairman and Managing Director, Zydus. “This molecule has a novel mechanism of action, rapidly kills parasites across all intra-erythrocytic stages and has a long half-life, which means it might even lead to a single-dose cure for P. falciparum malaria.”

For the full story please visit : http://www.mmv.org/newsroom/press-releases/mmv-and-zydus-join-forces-develop-new-antimalarial

[source : http://www.mmv.org/newsroom/press-releases/mmv-and-zydus-join-forces-develop-new-antimalarial, http://www.dnaindia.com/money/report-zydus-cadila-goes-for-collaboration-for-anti-malaria-drug-2260089]

11 Jul 2016

MMV and Novartis expand partnership

MMV and Novartis recently announced an expansion to their current partnership. Novartis will be taking the lead in the development of the antimalarial compound KAF156, which has scientific and financial support from MMV and Bill and Melinda Gates Foundation.

According to Joseph Jimenez, CEO of Novartis: “With a child dying from malaria every two minutes and the threat of drug resistance growing year-on-year, there is a real urgency to step up global efforts to combat this disease. Partnerships and collaborations like this one with MMV are essential for the development of next generation antimalarials and accelerating efforts to eradicate this deadly disease.”

KAF156 is one of the first antimalarial drugs to enter Phase IIb clinical development in more than 20 years, working against two parasites that are responsible for the majority of malaria deaths, Plasmodium falciparum and Plasmodium vivax. KAF156 continues in the footsteps of Novartis’s first fixed-dose Artemisinin-based Combination Therapy, Coartem®, which was launched in 1999.

Dr. David Reddy, CEO of MMV, added: “We are delighted to extend our partnership with Novartis in the development of this exciting candidate antimalarial medicine with the potential to tackle drug resistance and improve patient compliance. As such, this agreement marks an important milestone, as MMV continues its mission to discover, develop and deliver new, effective and affordable antimalarials to the patients who need them most.”

For more information on this, please go to: http://www.mmv.org/newsroom/press-releases/mmv-and-novartis-expand-partnership

24 Feb 2016


The first paediatric antimalarial that has been granted a positive scientific opinion from the European Medicines Agency (EMA), under Article 58 is Pyramax® Granules. Pyramax® Granules is a fixed-dose artemisinin combination therapy (ACT) of pyronaridine and artesunate. With this opinion, the registration and use of Pyramax® Granules on children in malaria stricken areas will be supported.

Given the fact that a child would need to complete the full dose in order to attain a cure, it is appropriate that the granule formulation is taste-masked, suspends in only 2 teaspoons of liquid and only requires a once daily dose for 3 days, making treatment compliance simple for sick children.

According to Medicines for Malaria Venture’s CEO, David Reddy, “Around 78% of people dying from malaria are children less than 5 years of age. The timely development of age-appropriate formulations to address the needs of this particularly vulnerable population is essential. Following this positive scientific opinion from EMA, MMV, Shin Poong and other partners can work with endemic countries to pursue national approvals for Pyramax Granules and make the medicine available to children in need.”

Jei Man Ryu, CEO of Shin Poong Pharmaceutical, commented the following, “We are proud to have reached this landmark achievement with our long-standing partner Medicines for Malaria Venture. We have worked with dedication to achieve this goal and will continue to collaborate with MMV to ensure that this important life-saving medicine reaches the children for whom we developed it. Unacceptable numbers of children continue to die of malaria and this medicine will be of enormous benefit to those children suffering from either P. vivax or P. falciparum blood-stage malaria.”

For more information on this, please go to: http://www.mmv.org/newsroom/press-releases/pyramax-granules-becomes-first-paediatric-antimalarial-receive-ema-article